| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
11.05(B) |
| Last
Volume: |
369,691 |
Avg
Vol: |
419,170 |
| 52
Week Range: |
$205.19 - $256.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
458,205 |
492,210 |
585,467 |
1,744,588 |
| Total Sell Value |
$108,580,139 |
$116,427,987 |
$137,373,790 |
$425,241,289 |
| Total People Sold |
5 |
6 |
6 |
10 |
| Total Sell Transactions |
46 |
54 |
71 |
244 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-10 |
4 |
OE |
$129.49 |
$1,786,962 |
D/D |
13,800 |
13,930 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-09 |
4 |
AS |
$236.74 |
$3,557,356 |
D/D |
(15,000) |
130 |
|
-1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-09 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-08 |
4 |
AS |
$232.43 |
$1,201,845 |
D/D |
(5,060) |
130 |
|
-1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-08 |
4 |
OE |
$129.49 |
$655,219 |
D/D |
5,060 |
5,190 |
|
- |
|
| Dwek Raymond |
|
– • – |
2024-04-08 |
4 |
D |
$236.96 |
$947,840 |
D/D |
(4,000) |
1,750 |
|
- |
|
| Dwek Raymond |
|
– • – |
2024-04-08 |
4 |
OE |
$88.03 |
$352,120 |
D/D |
4,000 |
5,750 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-05 |
4 |
AS |
$231.31 |
$3,525,890 |
D/D |
(15,000) |
130 |
|
0% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-05 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-04-04 |
4 |
AS |
$228.84 |
$1,394,248 |
D/D |
(6,000) |
36,710 |
|
-0% |
|
| Mahon Paul A |
EVP & GENERAL COUNSEL |
• – – |
2024-04-04 |
4 |
OE |
$117.76 |
$706,560 |
D/D |
6,000 |
42,710 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-04 |
4 |
AS |
$230.65 |
$3,499,075 |
D/D |
(15,000) |
130 |
|
-0% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-04 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-03 |
4 |
AS |
$223.73 |
$3,458,635 |
D/D |
(15,000) |
130 |
|
1% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-03 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-02 |
4 |
AS |
$227.02 |
$3,441,093 |
D/D |
(15,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-02 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-01 |
4 |
AS |
$223.03 |
$3,419,732 |
D/D |
(15,000) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-04-01 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-28 |
4 |
AS |
$230.61 |
$3,336,053 |
D/D |
(14,125) |
130 |
|
2% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-28 |
4 |
OE |
$129.49 |
$1,829,046 |
D/D |
14,125 |
14,255 |
|
- |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-27 |
4 |
AS |
$237.15 |
$3,626,246 |
D/D |
(15,000) |
130 |
|
-4% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-27 |
4 |
OE |
$129.49 |
$1,942,350 |
D/D |
15,000 |
15,130 |
|
- |
|
| Mesa Nilda |
|
– • – |
2024-03-27 |
4 |
S |
$237.80 |
$77,285 |
D/D |
(325) |
5,373 |
|
3% |
|
| Rothblatt Martine A |
CHAIRPERSON & CEO |
• • – |
2024-03-26 |
4 |
AS |
$244.67 |
$3,724,939 |
D/D |
(15,000) |
130 |
|
-6% |
|
4998 Records found
|
|
Page 2 of 200 |
|
|
2.10 (0.89%) 
